Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:5/1/2012

SAN DIEGO, May 1, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has exercised its option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the contract supporting the development of a robust Pfēnex Expression Technology™ based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will continue to develop an rPA-based anthrax vaccine from rPA produced in Pseudomonas fluorescens.  During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPA.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U.S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. OptiScan Biomedical Presents Study Results Demonstrating OptiScanners Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients
2. Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies
3. What Recession? How Biomedical Device Companies Thrived in a Bad Economy
4. Crux Biomedicals IVC Filter Receives CE Mark Approval
5. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
6. Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation
7. Pepex Biomedical Signs Seven Year Deal to Manufacture "Trio™"
8. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
9. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
10. U.S. Biomedical Leaders Present Leaders on Capitol Hill with New National Strategy for Innovation
11. Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... MicroDose Technologies,Inc. (MicroDose) today announced that the first ... Inc., through a Merck affiliate, has been,achieved, triggering ... MicroDose,s dry powder inhaler (DPI) technology announced in ... of a Phase I clinical,study of an investigational ...
... -Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular ... ... SUNNYVALE, Calif., Aug. 5 Icon Bioscience, Inc., (IBI),a privately ... its Phase I clinical trial to assess the,safety and efficacy of ...
Cached Medicine Technology:MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate 2
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... one out of three survivors of critical illness, ... The Lancet Respiratory Medicine , and the majority ... mentally. , It is one of the largest ... outcomes of critical care survivors, according to lead ... and it highlights a significant public health issue, ...
(Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
(Date:4/23/2014)... 24, 2014 Pregnant immigrants from Sub-Saharan Africa, ... monitoring during pregnancy, according to new research from ... in the British Journal of Obstetrics and ... eclampsia rates among immigrants and native-born women in ... Denmark, Sweden, Spain (Catalonia and Valencia) and the ...
(Date:4/23/2014)... Society for Radiation Oncology (ASTRO) has issued a ... for Endometrial Cancer: An ASTRO Evidence-Based Guideline," that ... the treatment of endometrial cancer. The guideline,s executive ... of Practical Radiation Oncology (PRO), the ... guideline is available as an open-access article online ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... the worldwide leader of post-breast surgery products, ... Collection, the industry,s first post-surgical garments infused ... discomfort after breast surgery.(Logo: ... http://www.newscom.com/cgi-bin/prnh/20090408/CL96087 )The post-surgical camisole and ...
... NORTH BRUNSWICK¿ N.J.¿ April 8 ORTHOCON¿ Inc. today ... company as President and Chief Executive Officer. The company ... of financing led by top-tier healthcare investors. ORTHOCON ... bone. The Company,s versatile technology platform may be leveraged ...
... for good nutrition but lack knowledge of food prep ... the current economic conditions, three-quarters of what people eat ... dependent on what food families keep in their kitchens. ... freezers, Rutgers University researchers found that, in ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today ... (BGM) in its Phase 2 clinical safety trial with ... BGM will measure levels of Galectin-3 in patients enrolled ... remodeling associated with advanced stages of heart failure. CDP-1050 ...
... NORTHFIELD, Ill., April 8 The College of American ... accreditation organization and deeming authority under the Clinical Laboratory ... and Medicaid Services (CMS) since 1995, has been notified ... subspecialties for a six-year period, the longest period available ...
... LAS VEGAS, April 8 Scheduled for June 5 ... garnered broad industry support and surpassed previous levels of ... this annual medical education and commercial exhibition event has ... a focal point for the high-growth medical aesthetic industry. ...
Cached Medicine News:Health News:Amoena Introduces First Post Surgical Garments With Vitamin E & Aloe to Help Soothe and Comfort After Breast Surgery 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 2Health News:Rutgers Study Reveals A Need For Basic Kitchen Know-How 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 2Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 3Health News:Cordex Pharma to Collaborate with BG Medicine in a Clinical Study of Heart Failure Biomarkers 4Health News:CAP Deeming Status Renewed 2Health News:THE Aesthetic Show Attracts Record Sponsorship 2Health News:THE Aesthetic Show Attracts Record Sponsorship 3
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: